Eli Lilly and Company (LLY) — closed signal from March 14, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on June 12, 2026.
Predicted vs. what happened
LLY price · publication thesis → realized outcomesplit-adjusted
$970.00 – $995.00Entry zone — fair-value band
$985.08Published — price the day we called it
$1,103.29Target — the price the thesis aimed for
$1,182.73Peak — highest point inside the window, not a realized return
$1,133.00Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 75 days.
Peak price
$1,182.73
peak on June 8, 2026 — not a realized returnPeak gain
+20.1%
peak, from the publication priceWindow close
$1,133.00
end-of-window price, context onlyDays to target
75
Window
March 14, 2026 – June 12, 2026
The thesis — published March 14, 2026
Predicted growth
+12%
over the measurement windowTarget price
$1,103.29
the price the thesis aimed forEntry zone
$970.00 – $995.00
the fair-value band we waited forPrice at publication
$985.08
published March 14, 2026Confidence
76%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Eli Lilly is a steady company because its weight-loss and diabetes drugs still drive sales, and recent deal talk keeps future drug chances open. The stock has fallen enough to look like a better buy now, but gains may come slowly over the next quarter, so expect steady recovery rather than a quick jump.
Primary drivers
- Weight-loss and diabetes drugs provide consistent revenue and growth
- News keeps drug development possibilities active and visible
- Large-company status can attract investment when markets wobble
- The recent drop makes it a clearer, less rushed buying opportunity
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.